Abdelli Latifa S, Singla Dinender K
Burnett School of Biomedical Sciences, Biomolecular Science Center, College of Medicine, University of Central Florida, 4110 Libra Drive, Building #20; Room # 320A, Orlando, FL, 32816, USA.
Mol Cell Biochem. 2015 Aug;406(1-2):101-9. doi: 10.1007/s11010-015-2428-9. Epub 2015 Apr 29.
Cardiac cell regeneration from endogenous cardiac stem cells (CSCs) following MI is rather low. Therefore, identifying mechanisms to boost endogenous CSC activation and participation in cardiac repair appears to be the most promising strategy for MI patients. We previously engineered tissue inhibitor of metalloproteinases-1 (TIMP-1) overexpressing embryonic stem (ES-TIMP-1) cells and transplanted them into the infarcted murine heart. Collected data demonstrated that TIMP-1 enhanced transplanted ES cell engraftment, survival and differentiation into cardiac myocytes post-transplantation. Therefore, we postulated that there may be a new stem cell population present in the heart that is regulated by extracellular protein TIMP-1. Furthermore, we hypothesized that this cell population has a potential for cell proliferation and differentiation into cardiac cell types. Therefore, we isolated CSCs from 4 weeks old C57BL/6 mice and cultured them in vitro in presence of ESCM, ES-TIMP-1-CM or TIMP-1. Our immunostaining data demonstrated the existence of a novel CSC subpopulation, CD63(+ve)/c-kit(+ve). When treated with TIMP-1, these cells showed significantly (p < 0.05) increased proliferation rates compared to control cells, enhanced TIMP-1 receptor (CD63), along with improved expression of phospho and total β-catenin proteins as demonstrated by Western blot analysis. Next, we demonstrate significantly (p < 0.05) improved cardiac myocyte, vascular smooth muscle cell, and endothelial cell differentiation. Furthermore, our RT-PCR data shows increase in cardiac gene (GATA-4, Mef2C, and Nkx-2.5) expression when compared to ESCM and control cells. Collectively, these data, for the first time, establish the existence of a new CD63(+ve)/c-kit(+ve) CSC subpopulation that has a significant potential for proliferation and differentiation into cardiac cell types once stimulated with TIMP-1.
心肌梗死后源自内源性心脏干细胞(CSCs)的心脏细胞再生相当低。因此,确定促进内源性CSC激活并参与心脏修复的机制似乎是对心肌梗死患者最有前景的策略。我们之前构建了过表达金属蛋白酶组织抑制剂-1(TIMP-1)的胚胎干细胞(ES-TIMP-1细胞),并将其移植到梗死的小鼠心脏中。收集的数据表明,TIMP-1增强了移植后ES细胞的植入、存活以及向心肌细胞的分化。因此,我们推测心脏中可能存在一个受细胞外蛋白TIMP-1调节的新干细胞群体。此外,我们假设这个细胞群体具有细胞增殖以及分化为心脏细胞类型的潜力。因此,我们从4周龄的C57BL/6小鼠中分离出CSCs,并在胚胎干细胞条件培养基(ESCM)、ES-TIMP-1条件培养基(ES-TIMP-1-CM)或TIMP-1存在的情况下进行体外培养。我们的免疫染色数据证明存在一个新的CSC亚群,即CD63(阳性)/c-kit(阳性)。与对照细胞相比,用TIMP-1处理时,这些细胞显示出显著(p<0.05)提高的增殖率,TIMP-1受体(CD63)增强,同时如蛋白质免疫印迹分析所示,磷酸化和总β-连环蛋白蛋白的表达也有所改善。接下来,我们证明心肌细胞、血管平滑肌细胞和内皮细胞的分化有显著(p<0.05)改善。此外,我们的逆转录聚合酶链反应(RT-PCR)数据显示,与ESCM和对照细胞相比,心脏基因(GATA-4、Mef2C和Nkx-2.5)的表达增加。总体而言,这些数据首次证实了新的CD63(阳性)/c-kit(阳性)CSC亚群的存在,该亚群一旦受到TIMP-1刺激,具有显著的增殖以及分化为心脏细胞类型的潜力。